Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in patients with Sézary syndrome at ASH 2023
Innate Pharma To Host Virtual Kol Event On Lacutamab
Innate Pharma reports third quarter 2023 financial results and business update
Innate Pharma announces conference call for Third Quarter 2023 Business Update
Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023
Innate Pharma announces its participation to upcoming investor conferences
Innate Pharma 2024 Financial Calendar
Innate Pharma announces abstracts selected for ESMO congress 2023
Number of shares and voting rights of Innate Pharma as of October 3, 2023
Innate Pharma provides update on lacutamab clinical program
